SCHEMBL24400855

SCHEMBL24400855

Cc1nc2ocnc2n1C

nearest known ligand 0.30

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
CDK9 P50750 1/20 0.30
DYRK1A Q13627 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18059158 0.74 CDK9 (0.38) CDK9DYRK1A
SCHEMBL24400865 0.68
SCHEMBL5040001 0.62 KDM4E (0.40)
SCHEMBL24400858 0.62
SCHEMBL24400866 0.60
SCHEMBL25297700 0.59 NR3C1 (0.37) CDK9DYRK1A
SCHEMBL19117710 0.58 ADORA2A (0.33)
SCHEMBL5036801 0.58
SCHEMBL13662357 0.58
SCHEMBL19267557 0.58 CDK9 (0.32) CDK9DYRK1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230203057-A1 FIVE-MEMBERED HETEROAROMATIC IMIDAZOLE COMPOUND AND USE THEREOF HANGZHOU SCIWIND BIOSCIENCES CO., LTD (CN) 2023-06-29 US disclosed
US-11542272-B2 Five-membered heteroaryl-fused imidazole compound and application thereof HANGZHOU SCIWIND BIOSCIENCES CO., LTD (CN) 2023-01-03 US disclosed
US-20220135588-A1 Five-Membered Heteroaryl-Fused Imidazole Compound And Application Thereof HANGZHOU SCIWIND BIOSCIENCES CO., LTD (CN) 2022-05-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220135588-A1 Five-Membered Heteroaryl-Fused Imidazole Compound And Application Thereof GLP1R, GIPR, GPR119 CDK9 2484/4885DYRK1A 1540/4885
US-20230203057-A1 FIVE-MEMBERED HETEROAROMATIC IMIDAZOLE COMPOUND AND USE THEREOF GLP1R, GIPR, GPR119 CDK9 1873/4885DYRK1A 1688/4885
US-11542272-B2 Five-membered heteroaryl-fused imidazole compound and application thereof GLP1R, GIPR, GPR119 CDK9 2484/4885DYRK1A 1540/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.